Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs Triamcinolone for Persistent Diabetic Macular Edema
NCT02985619Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
01
Overview
A Phase 3 trial of triamcinolone, bevacizumab in diabetic macular edema (DME), sponsored by Universidade de São Paulo. Started Jul 2016; status: completed.
02
Drugs
triamcinolonebevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02985619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985619.